Health News

Rx Combo Slowed Multiple Myeloma
When it comes to treating multiple myeloma, three medications may be better than two.
Eric Berry Diagnosed With Hodgkin Lymphoma
Kansas City Chiefs safety Eric Berry has been diagnosed with Hodgkin lymphoma. Fortunately, his medical team has an optimistic outlook.
FDA Approves Blincyto to Treat Rare Form of Leukemia
The U.S. Food and Drug Administration today approved Blincyto (blinatumomab) to treat patients with Philadelphia chromosome-negative precursor B-cell acute lymphoblastic leukemia (B-cell ALL), an uncommon form of ALL.
Immune Diseases Were More Common in Those Born by C-Section
Could the birth process have a role in immune disease development? A common birthing method may raise babies' risk of immune diseases later, a new study found.
FDA Expands Approval of Rx for Rare Blood and Bone Disease
Earlier this year, the US Food and Drug Administration (FDA) gave a speedy approval to a new medication to treat a rare blood disease. Now, the FDA has expanded that approval.
FDA Approves New Cancer Medication
The US Food and Drug Administration (FDA) approved Zydelig (idelalisib) today to treat patients with three types of blood cancers.
FDA Approves Belinostat for Rare Form of Non-Hodgkin Lymphoma
The U.S. Food and Drug Administration today approved Beleodaq (belinostat) for the treatment of patients with peripheral T-cell lymphoma (PTCL), a rare and fast-growing type of non-Hodgkin lymphoma (NHL).
Many Minority Kids With Cancer Missed Needed Medication
Children in remission from leukemia, the most common childhood cancer, need to take a certain medication to keep the cancer from coming back. But some of these children are not receiving all the medication they need.
Mega-Dose of Measles Vaccine Killed Cancer
Multiple myeloma is a cancer that develops in the bone marrow and is considered by many to be incurable. An engineered measles virus, however, may change that.
FDA Approves Sylvant for Rare Castleman’s Disease
The U.S. Food and Drug Administration today approved Sylvant (siltuximab) to treat patients with multicentric Castleman’s disease (MCD), a rare disorder similar to lymphoma (cancer of the lymph nodes).